CAR T Cells and Bispecific Antibodies: New Options in Multiple Myeloma
Adam D. Cohen, MD, discusses the new era of multiple myeloma treatment with bispecifics and CAR T-cell therapy.
The past few years have seen a surge in new treatments for multiple myeloma, especially with chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies. These therapies are particularly effective for patients with relapsed or treatment-resistant myeloma and offer new hope for patients with multiple myeloma.
Here, Adam D. Cohen, MD, associate professor of medicine at the Hospital of the University of Pennsylvania, discusses the new era of multiple myeloma treatment with bispecifics and CAR T-cell therapy, as discussed at the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, hosted by Dr. Guenther Koehne and Miami Cancer Institute.
Transcription:
0:09 | There has really been an explosion of new therapies for multiple myeloma and especially the past 3 or 4 years. Particularly, what I'll be talking about are the T-cell redirecting therapies, so CAR T cells and bispecific antibodies. We have had 5 of these now approved in the past few years, and they are making a big difference for our patients, particularly with relapsed/refractory myeloma.
0:31 | In 2023, we saw the approval of 2 new bispecific antibodies for multiple myeloma. One is called elrenatomab, a BCMA-targeted treatment, and 1 is called talquetamab, hitting a new target, GPRC5D, and these telquistamab, which was the prior bispecific antibody that was approved in late 2022. So now we have 3 of these off-the-shelf, very potent T-cell engaging bispecific antibodies to treat myeloma.
1:00 | In addition, we saw some new data for the CAR T cells in multiple myeloma, particularly data from the first randomized clinical trials, comparing these agents, ide-cel and cilta-cel to our older standard of care regimens for less heavily pretreated patients and showing significant progression-free survival advantages for the CAR T cells. Again, just re enforcing what we have already been doing, which is using these agents hopefully a little bit earlier.
